top of page

Resource Hub

For more on the resources IPAC provides and links to external information please read more below. 

IPAC Publications and Case Studies

IPAC joined with several health community stakeholders calling on policymakers to ensure access to critical medicines, including MDIs, while achieving important climate goals with a revised EU Flourinated Greenhouse Gases Regulation.

In 4Q 2021, the International Pharmaceutical Aerosol Consortium (IPAC) conducted a survey of its member companies regarding the manufacture of HFC MDIs in the European Union, including volumes imported and exported. This document summarises the compiled, aggregate survey responses from IPAC members. All data refers to calendar year 2020.

On 5 May 2021, IPAC presented this work at the Respiratory Drug Delivery conference.  The paper provides context on the evolving global legislative and regulatory landscape relevant to medical propellants and shares IPAC’s views on the most effective holistic, patient-care approach to the global environmental challenges of inhaled therapies.

The Return Campaign is an initiative driven by the UK members of IPAC with Asthma UK and the British Lung Foundation, as well as stakeholders in the National Health Service, to raise awareness for the ability to return inhalers that are used or no longer needed to a local pharmacy in order to be disposed of in the most environmentally conscious way. The campaign, shared via social media, will allow patients to be aware of the existing infrastructure available and help the environmental impact of inhaled therapies in the United Kingdom. 

Contact IPAC at to view the campaign materials. 

Please see FAQs here on returning your inhalers under the NHS Medicine Waste Scheme. 

In May 2021, IPAC joined clinicians, policymakers, and patients in a live panel discussion organized by European Respiratory Society to consider the implications of climate change for asthma patients and shared perspectives on ways to achieve environmental progress and optimise patient care.

The American Innovation and Manufacturing Act directs the United States Environmental Protection Agency (EPA) to establish a national program phasing down the production and consumption of hydrofluorocarbons.  The law creates a “mandatory allocation” for hydrofluorocarbons for metered dose inhalers to ensure adequate supplies of hydrofluorocarbons metered dose inhalers are available to meet patient need.  The Environmental Protection Agency issued a public rulemaking process to establish the process and also requested data from metered dose inhaler companies to understand the levels of hydrofluorocarbons needed. The deadline for submissions was 6 July 2021 and hydrofluorocarbons allocations will be issued to individual metered dose inhaler companies by 23 September 2021.  IPAC and its members submitted data and comments to the Environmental Protection Agency process.  


Further details are available here.


IPAC-RS was formed as part of the International Pharmaceutical Aerosol Consortium (IPAC) in 1999 and established in 2001 as a separate Consortium, with the mission to enhance the quality and availability to patients of orally inhaled and nasal drug products (OINDP) through scientifically driven advancements related to development and regulation of these products. 

External Resources and Information

bottom of page